The Post-9/11 VA Opioid Crisis — Catalyst for Cannabis Advocacy

The VA's adoption of "pain as the fifth vital sign" in 1998, combined with the Joint Commission's 2001 mandate linking pain assessment to reimbursement, unleashed an opioid prescribing crisis among veterans. Opioid prescriptions quadrupled, veteran overdose rates doubled, and the catastrophe catalyzed a generation of veteran cannabis advocacy framing cannabis as a safer alternative to the opioids the VA system itself had overprescribed.

The "Pain as the Fifth Vital Sign" Policy

In 1998, the VA adopted "pain as the fifth vital sign" as a clinical care philosophy. The idea — which originated in palliative care and spread through the Joint Commission's 2001 hospital accreditation standards — was that pain should be assessed routinely and aggressively treated. The intention was humane: many patients in the 1990s had pain that was undertreated, particularly in cancer and chronic conditions.

But the implementation collided with aggressive marketing of opioid analgesics — particularly OxyContin, marketed by Purdue Pharma with claims that it had low addiction potential when used for pain. The result was a systematic expansion of opioid prescribing across U.S. healthcare, and VA was no exception.

The Scale of VA Opioid Prescribing

Opioid prescriptions written by military physicians quadrupled between 2001 and 2009 to nearly 3.8 million per year. By 2008:

• More than 1 in 10 service members was taking opioids
• Among those prescribed opioids while awaiting medical discharge, 25–35% met criteria for substance dependence
• Post-deployment chronic pain rates were approaching 60% in some OEF/OIF populations

This was not a handful of bad actors prescribing irresponsibly — it was systematic overprescription embedded in clinical practice guidelines and quality metrics.

The Mortality Consequences

The consequences were catastrophic:

• By FY2005, the VHA opioid overdose mortality rate was nearly twice that of the general population
• Between 2010 and 2015, veterans with opioid use disorder increased 55%, reaching approximately 68,000 veterans — a threefold increase in 12 years
• Veterans remain twice as likely as non-veterans to die from accidental opioid overdose
• Chronic pain affects approximately 60% of returning Middle East deployment veterans

These numbers represent a public health catastrophe on top of the combat-related psychological costs of the post-9/11 wars. Some veterans returned from deployment with traumatic injuries, survived, and then died of opioid overdoses prescribed to treat their injuries.

The VA Opioid Safety Initiative (2013)

The VA launched its Opioid Safety Initiative in 2013 in response to the scale of the crisis. The initiative aimed to:

• Reduce initiation of opioid therapy for chronic noncancer pain
• Reduce doses for existing chronic opioid patients
• Eliminate co-prescribing of opioids with benzodiazepines (which dramatically increases overdose risk)
• Expand non-pharmacological pain management alternatives
• Improve monitoring and risk assessment
• Provide medication-assisted treatment for opioid use disorder

The Opioid Safety Initiative was remarkably successful in its main goals:

• Veterans dispensed opioids decreased 56%
• Co-prescribed opioids/benzodiazepines decreased 83%
• Veterans on high-dose opioids decreased 77%

The VA/DoD 2022 Clinical Practice Guideline now recommends against initiation of opioid therapy for chronic noncancer pain, reflecting the dramatic shift away from opioid-first pain management.

The Unintended Consequences

The opioid safety initiative was a policy success, but it also produced unintended consequences:

• Veterans who had been stable on long-term opioid therapy were sometimes tapered too aggressively, leading to uncontrolled pain and in some cases suicide
• Some veterans who lost VA opioid prescriptions turned to illicit opioids (heroin, fentanyl), often with fatal consequences
• Some veterans turned to cannabis specifically as a perceived safer alternative to opioids
• The rapid policy shift produced significant variability in how individual clinicians implemented the new guidance

These consequences fueled a parallel conversation: if VA was moving away from opioids, what alternatives would veterans have for chronic pain management? The answer, for many veteran advocates, became cannabis.

The Cannabis-as-Alternative Argument

The opioid crisis catalyzed a generation of veteran cannabis advocacy with a specific argument: cannabis is safer than opioids, and VA policy should recognize this. Key claims:

• Cannabis overdose deaths are essentially nonexistent compared to opioid deaths
• Cannabis may provide pain relief for some conditions
• Ecological studies (Bachhuber 2014 — see chronic pain page) suggested that medical cannabis state laws were associated with lower opioid overdose mortality
• Patient surveys showed that medical cannabis users often reported reducing opioid use after starting cannabis
• Veterans should have access to safer alternatives, and if the VA would not recommend cannabis, state medical programs should

This framing was highly effective politically. It moved cannabis advocacy from "stoners want legalization" to "veterans are dying and VA is refusing to offer a safer option." It unified veterans across political spectrums around a specific policy demand. It provided rhetorical cover for state legalization efforts (especially medical programs). And it positioned veteran cannabis advocacy as explicitly aligned with harm reduction and patient safety.

The Evidence Is More Complicated

The "cannabis as opioid alternative" argument is emotionally compelling and partially supported by evidence. But the full picture is more complicated:

• The Shover et al. 2019 reanalysis (PMID 31182592) extended the Bachhuber data through 2017 and found the opioid mortality association reversed to +23%, concluding that the original finding was likely spurious
• Individual-level studies have not consistently shown that veterans who use cannabis for pain reduce their opioid use
• The patient-reported "I use less opioids with cannabis" finding is real but cannot establish causation
• Cannabis has its own harms, including CUD, drug interactions, and respiratory effects (when smoked)

The most honest summary: cannabis is not obviously safer than opioids in individual terms, though it has a much more favorable overdose profile. It is unclear whether widespread cannabis use for chronic pain would reduce opioid harms at the population level. The evidence supports cannabis as one tool in a broader harm-reduction approach, but not as a replacement for opioids or as proven safer in all respects. Chronic pain evidence review.

The Political Legacy

Despite the complicated evidence, the opioid crisis permanently changed the political landscape for veteran cannabis advocacy. The Veterans Equal Access Act, introduced every Congress since 2015, explicitly draws on this framing. The 2016 American Legion resolution supporting cannabis research was driven in significant part by opioid crisis concerns. The Cannabis Caucus and its veteran-focused members point to opioid harms when arguing for reform.

Whether or not cannabis is truly a "safer alternative" in the individual clinical sense, the political argument that it might be has reshaped how veteran cannabis policy is debated. The crisis validated the advocacy framework that "veterans need alternatives" — and that framework has become the primary justification for continued reform efforts.

Related Reading

• Cannabis & Chronic Pain
• Veteran Cannabis Advocates
• Advocacy Organizations
• Veterans Equal Access Act